Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-18

Clinical Trial Update: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-term rilonacept to prevent gout flares was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Arcalyst (rilonacept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Gout | Phase 3 | Status: TERMINATED | Results posted: 2017-07-18